Genomic aberrations guiding treatment of non-small cell lung cancer patients

Cancer Treatment Communications

Volumn 4, Issue , 2015, Pages 23-33

  Saber, Ali ^a   van der Wekken, Anthonie ^a   Hiltermann, Thijo J N ^a   Kok, Klaas ^a   van den Berg, Anke ^a   Groen, Harry J M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Next generation sequencing; Non small cell lung cancer; Resistance; Targeted therapy

Indexed keywords

AFATINIB; ALECTINIB; ANAPLASTIC LYMPHOMA KINASE INHIBITOR; B RAF KINASE INHIBITOR; CABOZANTINIB; CERITINIB; CRIZOTINIB; DABRAFENIB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; PONATINIB; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TIVANTINIB; TRAMETINIB; VANDETANIB; VEMURAFENIB;

ARTICLE; CANCER CELL; CARCINOGENESIS; CELL SURVIVAL; DRUG TARGETING; GENE MUTATION; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; META ANALYSIS (TOPIC); NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SMALL CELL LUNG CANCER; SQUAMOUS CELL LUNG CARCINOMA; TUMOR GROWTH;

EID: 84947939750     PISSN: 22130896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrc.2015.03.005     Document Type: Article

References (92)

1. Nana-Sinkam S.P., Powell C.A. Molecular Biology of Lung Cancer: Diagnosis and Management of Lung Cancer 2013, 143:e30S-e339. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 3rd ed.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 2013, 63:11-30.
3. Francis H., Solomon B. The current status of targeted therapy for non-small cell lung cancer. Intern. Med. J. 2010, 40:611-618.
4. Travis W.D. Pathology of lung cancer. Clin. Chest Med. 2011, 32:669-692.
5. Fischer B., Lassen U., Mortensen J., Larsen S., Loft A., Bertelsen A., Ravn J., Clementsen P., Hogholm A., Larsen K., Rasmussen T., Keiding S., Dirksen A., Gerke O., Skov B., Steffensen I., Hansen H., Vilmann P., Jacobsen G., Backer V., Maltbaek N., Pedersen J., Madsen H., Nielsen H., Hojgaard L. Preoperative staging of lung cancer with combined PET-CT. N. Engl. J. Med. 2009, 361:32-39.
6. Socinski M.A., Evans T., Gettinger S., Hensing T.A., Sequist L.V., Ireland B., Stinchcombe T.E. Treatment of stage IV non-small cell lung cancer: diagnosis and management of lung cancer 2013, 143:e341S-e3368. American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 3rd ed.
7. van der Drift M.A., Karim-Kos H.E., Siesling S., Groen H.J., Wouters M.W., Coebergh J.W., de Vries E. Janssen-Heijnen ML. Progress in standard of care therapy and modest survival benefits in the treatment of non-small cell lung cancer patients in the Netherlands in the last 20 years. J. Thorac. Oncol. 2012, 7:291-298.
8. Vokes E.E., Herndon J.E., Kelley M.J., Cicchetti M.G., Ramnath N., Neill H., Atkins J.N., Watson D.M., Akerley W., Green M.R. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: cancer and leukemia Group B. J. Clin. Oncol. 2007, 25:1698-1704.
9. Okudela K., Woo T., Kitamura H. KRAS gene mutations in lung cancer: particulars established and issues unresolved. Pathol. Int. 2010, 60:651-660.
10. Linzer D.I., Levine A.J. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 1979, 17:43-52.
11. Takahashi T., Suzuki H., Hida T., Sekido Y., Ariyoshi Y., Ueda R. The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern. Oncogene 1991, 6:1775-1778.
12. Der C.J., Krontiris T.G., Cooper G.M. Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses. Proc. Natl. Acad. Sci. USA 1982, 79:3637-3640.
13. Davies H., Hunter C., Smith R., Stephens P., Greenman C., Bignell G., Teague J., Butler A., Edkins S., Stevens C., Parker A., O'Meara S., Avis T., Barthorpe S., Brackenbury L., Buck G., Clements J., Cole J., Dicks E., Edwards K., Forbes S., Gorton M., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Jones D., Kosmidou V., Laman R., Lugg R., Menzies A., Perry J., Petty R., Raine K., Shepherd R., Small A., Solomon H., Stephens Y., Tofts C., Varian J., Webb A., West S., Widaa S., Yates A., Brasseur F., Cooper C.S., Flanagan A.M., Green A., Knowles M., Leung S.Y., Looijenga L.H., Malkowicz B., Pierotti M.A., Teh B.T., Yuen S.T., Lakhani S.R., Easton D.F., Weber B.L., Goldstraw P., Nicholson A.G., Wooster R., Stratton M.R., Futreal P.A. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res. 2005, 65:7591-7595.
14. Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.E., DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., Tan M.H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R. Patterns of somatic mutation in human cancer genomes. Nature 2007, 446:153-158.
15. Ding L., Getz G., Wheeler D.A., Mardis E.R., McLellan M.D., Cibulskis K., Sougnez C., Greulich H., Muzny D.M., Morgan M.B., Fulton L., Fulton R.S., Zhang Q., Wendl M.C., Lawrence M.S., Larson D.E., Chen K., Dooling D.J., Sabo A., Hawes A.C., Shen H., Jhangiani S.N., Lewis L.R., Hall O., Zhu Y., Mathew T., Ren Y., Yao J., Scherer S.E., Clerc K., Metcalf G.A., Ng B., Milosavljevic A., Gonzalez-Garay M.L., Osborne J.R., Meyer R., Shi X., Tang Y., Koboldt D.C., Lin L., Abbott R., Miner T.L., Pohl C., Fewell G., Haipek C., Schmidt H., Dunford-Shore B.H., Kraja A., Crosby S.D., Sawyer C.S., Vickery T., Sander S., Robinson J., Winckler W., Baldwin J., Chirieac L.R., Dutt A., Fennell T., Hanna M., Johnson B.E., Onofrio R.C., Thomas R.K., Tonon G., Weir B.A., Zhao X., Ziaugra L., Zody M.C., Giordano T., Orringer M.B., Roth J.A., Spitz M.R., Wistuba I.I., Ozenberger B., Good P.J., Chang A.C., Beer D.G., Watson M.A., Ladanyi M., Broderick S., Yoshizawa A., Travis W.D., Pao W., Province M.A., Weinstock G.M., Varmus H.E., Gabriel S.B., Lander E.S., Gibbs R.A., Meyerson M., Wilson R.K. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455:1069-1075.
16. Kan Z., Jaiswal B.S., Stinson J., Janakiraman V., Bhatt D., Stern H.M., Yue P., Haverty P.M., Bourgon R., Zheng J., Moorhead M., Chaudhuri S., Tomsho L.P., Peters B.A., Pujara K., Cordes S., Davis D.P., Carlton V.E., Yuan W., Li L., Wang W., Eigenbrot C., Kaminker J.S., Eberhard D.A., Waring P., Schuster S.C., Modrusan Z., Zhang Z., Stokoe D., de Sauvage F.J., Faham M., Seshagiri S. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 2010, 466:869-873.
17. Lipson D., Capelletti M., Yelensky R., Otto G., Parker A., Jarosz M., Curran J.A., Balasubramanian S., Bloom T., Brennan K.W., Donahue A., Downing S.R., Frampton G.M., Garcia L., Juhn F., Mitchell K.C., White E., White J., Zwirko Z., Peretz T., Nechushtan H., Soussan-Gutman L., Kim J., Sasaki H., Kim H.R., Park S.I., Ercan D., Sheehan C.E., Ross J.S., Cronin M.T., Janne P.A., Stephens P.J. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 2012, 18:382-384.
18. Bick D., Dimmock D. Whole exome and whole genome sequencing. Curr. Opin. Pediatr. 2011, 23:594-600.
19. Fox E.J., Reid-Bayliss K.S., Emond M.J., Loeb L.A. Accuracy of Next Generation Sequencing Platforms. Next Gen. Seq. Appl. 2014, 1.
20. Lee W., Jiang Z., Liu J., Haverty P.M., Guan Y., Stinson J., Yue P., Zhang Y., Pant K.P., Bhatt D., Ha C., Johnson S., Kennemer M.I., Mohan S., Nazarenko I., Watanabe C., Sparks A.B., Shames D.S., Gentleman R., de Sauvage F.J., Stern H., Pandita A., Ballinger D.G., Drmanac R., Modrusan Z., Seshagiri S., Zhang Z. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature 2010, 465:473-477.
21. Pleasance E.D., Stephens P.J., O'Meara S., McBride D.J., Meynert A., Jones D., Lin M.L., Beare D., Lau K.W., Greenman C., Varela I., Nik-Zainal S., Davies H.R., Ordonez G.R., Mudie L.J., Latimer C., Edkins S., Stebbings L., Chen L., Jia M., Leroy C., Marshall J., Menzies A., Butler A., Teague J.W., Mangion J., Sun Y.A., McLaughlin S.F., Peckham H.E., Tsung E.F., Costa G.L., Lee C.C., Minna J.D., Gazdar A., Birney E., Rhodes M.D., McKernan K.J., Stratton M.R., Futreal P.A., Campbell P.J. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 2010, 463:184-190.
22. Campbell P.J., Stephens P.J., Pleasance E.D., O'Meara S., Li H., Santarius T., Stebbings L.A., Leroy C., Edkins S., Hardy C., Teague J.W., Menzies A., Goodhead I., Turner D.J., Clee C.M., Quail M.A., Cox A., Brown C., Durbin R., Hurles M.E., Edwards P.A., Bignell G.R., Stratton M.R., Futreal P.A. Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat. Genet. 2008, 40:722-729.
23. Ju Y.S., Lee W.C., Shin J.Y., Lee S., Bleazard T., Won J.K., Kim Y.T., Kim J.I., Kang J.H., Seo J.S. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res. 2012, 22:436-445.
24. Liu P., Morrison C., Wang L., Xiong D., Vedell P., Cui P., Hua X., Ding F., Lu Y., James M., Ebben J.D., Xu H., Adjei A.A., Head K., Andrae J.W., Tschannen M.R., Jacob H., Pan J., Zhang Q., Van den Bergh F., Xiao H., Lo K.C., Patel J., Richmond T., Watt M.A., Albert T., Selzer R., Anderson M., Wang J., Wang Y., Starnes S., Yang P., You M. Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing. Carcinogenesis 2012, 33:1270-1276.
25. Govindan R., Ding L., Griffith M., Subramanian J., Dees N.D., Kanchi K.L., Maher C.A., Fulton R., Fulton L., Wallis J., Chen K., Walker J., McDonald S., Bose R., Ornitz D., Xiong D., You M., Dooling D.J., Watson M., Mardis E.R., Wilson R.K. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 2012, 150:1121-1134.
26. Vaddi K., Sarlis N.J., Ruxolitinib Gupta V. an oral JAK1 and JAK2 inhibitor, in myelofibrosis. Expert Opin. Pharmacother. 2012, 13:2397-2407.
27. TCGA Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012, 489:519-525.
28. Eichenmuller M., Trippel F., Kreuder M., Beck A., Schwarzmayr T., Haberle B., Cairo S., Leuschner I., von Schweinitz D., Strom T.M., Kappler R. The genomic landscape of hepatoblastoma and their progenies with HCC-like features. J. Hepatol. 2014.
29. Imielinski M., Berger A.H., Hammerman P.S., Hernandez B., Pugh T.J., Hodis E., Cho J., Suh J., Capelletti M., Sivachenko A., Sougnez C., Auclair D., Lawrence M.S., Stojanov P., Cibulskis K., Choi K., de Waal L., Sharifnia T., Brooks A., Greulich H., Banerji S., Zander T., Seidel D., Leenders F., Ansen S., Ludwig C., Engel-Riedel W., Stoelben E., Wolf J., Goparju C., Thompson K., Winckler W., Kwiatkowski D., Johnson B.E., Janne P.A., Miller V.A., Pao W., Travis W.D., Pass H.I., Gabriel S.B., Lander E.S., Thomas R.K., Garraway L.A., Getz G., Meyerson M. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012, 150:1107-1120.
30. Kim Y., Hammerman P.S., Kim J., Yoon J.A., Lee Y., Sun J.M., Wilkerson M.D., Pedamallu C.S., Cibulskis K., Yoo Y.K., Lawrence M.S., Stojanov P., Carter S.L., McKenna A., Stewart C., Sivachenko A.Y., Oh I.J., Kim H.K., Choi Y.S., Kim K., Shim Y.M., Kim K.S., Song S.Y., Na K.J., Choi Y.L., Hayes D.N., Cho S., Kim Y.C., Ahn J.S., Ahn M.J., Getz G., Meyerson M., Park K. Integrative and comparative genomic analysis of lung squamous cell carcinomas in East asian patients. J. Clin. Oncol. 2014, 32:121-128.
31. Singh D., Chan J.M., Zoppoli P., Niola F., Sullivan R., Castano A., Liu E.M., Reichel J., Porrati P., Pellegatta S., Qiu K., Gao Z., Ceccarelli M., Riccardi R., Brat D.J., Guha A., Aldape K., Golfinos J.G., Zagzag D., Mikkelsen T., Finocchiaro G., Lasorella A., Rabadan R., Iavarone A. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 2012, 337:1231-1235.
32. Williams S.V., Hurst C.D., Knowles M.A. Oncogenic FGFR3 gene fusions in bladder cancer. Hum. Mol. Genet. 2013, 22:795-803.
33. Janku F., Garrido-Laguna I., Petruzelka L.B., Stewart D.J., Kurzrock R. Novel therapeutic targets in non-small cell lung cancer. J. Thorac. Oncol. 2011, 6:1601-1612.
34. Savas P., Hughes B., Solomon B. Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer. J. Thorac. Dis. 2013, 5:S579-S592.
35. Lee C.K., Brown C., Gralla R.J., Hirsh V., Thongprasert S., Tsai C.M., Tan E.H., Ho J.C., Chu da T., Zaatar A., Osorio Sanchez J.A., Vu V.V., Au J.S., Inoue A., Lee S.M., Gebski V., Yang J.C. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J. Natl. Cancer Inst. 2013, 105:595-605.
36. Beau-Faller M., Prim N., Ruppert A.M., Nanni-Metellus I., Lacave R., Lacroix L., Escande F., Lizard S., Pretet J.L., Rouquette I., de Cremoux P., Solassol J., de Fraipont F., Bieche I., Cayre A., Favre-Guillevin E., Tomasini P., Wislez M., Besse B., Legrain M., Voegeli A.C., Baudrin L., Morin F., Zalcman G., Quoix E., Blons H., Cadranel J. Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10,117 patients: a multicentre observational study by the French ERMETIC-IFCT network. Ann. Oncol. 2014, 25:126-131.
37. Dahabreh I.J., Linardou H., Kosmidis P., Bafaloukos D., Murray S. EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer. Ann. Oncol. 2011, 22:545-552.
38. Sholl L.M., Xiao Y., Joshi V., Yeap B.Y., Cioffredi L.A., Jackman D.M., Lee C., Janne P.A., Lindeman N.I. EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry. Am. J. Clin. Pathol. 2010, 133:922-934.
39. Chaft J.E., Oxnard G.R., Sima C.S., Kris M.G., Miller V.A., Riely G.J. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin. Cancer Res. 2011, 17:6298-6303.
40. Rosell R., Bivona T.G., Karachaliou N. Genetics and biomarkers in personalisation of lung cancer treatment. Lancet 2013, 382:720-731.
41. Morinaga R., Okamoto I., Furuta K., Kawano Y., Sekijima M., Dote K., Satou T., Nishio K., Fukuoka M., Nakagawa K. Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation. Lung Cancer 2007, 58:411-413.
42. Zakowski M.F., Ladanyi M., Kris M.G. EGFR mutations in small-cell lung cancers in patients who have never smoked. N. Engl. J. Med. 2006, 355:213-215.
43. Zhang Z., Lee J.C., Lin L., Olivas V., Au V., LaFramboise T., Abdel-Rahman M., Wang X., Levine A.D., Rho J.K., Choi Y.J., Choi C.M., Kim S.W., Jang S.J., Park Y.S., Kim W.S., Lee D.H., Lee J.S., Miller V.A., Arcila M., Ladanyi M., Moonsamy P., Sawyers C., Boggon T.J., Ma P.C., Costa C., Taron M., Rosell R., Halmos B., Bivona T.G. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat. Genet. 2012, 44:852-860.
44. Bivona T.G., Hieronymus H., Parker J., Chang K., Taron M., Rosell R., Moonsamy P., Dahlman K., Miller V.A., Costa C., Hannon G., Sawyers C.L. FAS and NF-kappaB signalling modulate dependence of lung cancers on mutant EGFR. Nature 2011, 471:523-526.
45. Baumgart A., Seidl S., Vlachou P., Michel L., Mitova N., Schatz N., Specht K., Koch I., Schuster T., Grundler R., Kremer M., Fend F., Siveke J.T., Peschel C., Duyster J., Dechow T. ADAM17 regulates epidermal growth factor receptor expression through the activation of Notch1 in non-small cell lung cancer. Cancer Res. 2010, 70:5368-5378.
46. Serizawa M., Koh Y., Kenmotsu H., Isaka M., Murakami H., Akamatsu H., Mori K., Abe M., Hayashi I., Taira T., Maniwa T., Takahashi T., Endo M., Nakajima T., Ohde Y., Yamamoto N. Assessment of mutational profile of Japanese lung adenocarcinoma patients by multitarget assays: a prospective, single-institute study. Cancer 2014, 120:1471-1481.
47. Paik P.K., Arcila M.E., Fara M., Sima C.S., Miller V.A., Kris M.G., Ladanyi M., Riely G.J. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J. Clin. Oncol. 2011, 29:2046-2051.
48. Gautschi O., Pauli C., Strobel K., Hirschmann A., Printzen G., Aebi S., Diebold J. A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib. J. Thorac. Oncol. 2012, 7:e23-e24.
49. Peters S., Michielin O., Zimmermann S. Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma. J. Clin. Oncol. 2013, 31:e341-e344.
50. Planchard D., Mazieres J., Riely G.J. al. e. Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation-positive non-small cell lung cancer (NSCLC) patients. J. Clin. Oncol. 2013, 31.
51. Marchetti A., Felicioni L., Malatesta S., Grazia Sciarrotta M., Guetti L., Chella A., Viola P., Pullara C., Mucilli F., Buttitta F. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J. Clin. Oncol. 2011, 29:3574-3579.
52. Lin L., Asthana S., Chan E., Bandyopadhyay S., Martins M.M., Olivas V., Yan J.J., Pham L., Wang M.M., Bollag G., Solit D.B., Collisson E.A., Rudin C.M., Taylor B.S., Bivona T.G. Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. Proc. Natl. Acad. Sci. USA 2014, 111:E748-E757.
53. Rudin C.M., Hong K., Streit M. Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer. J. Thorac. Oncol. 2013, 8:e41-e42.
54. Giroux S. Overcoming acquired resistance to kinase inhibition: the cases of EGFR, ALK and BRAF. Bioorg. Med. Chem. Lett. 2013, 23:394-401.
55. Kwak E.L., Bang Y.J., Camidge D.R., Shaw A.T., Solomon B., Maki R.G., Ou S.H., Dezube B.J., Janne P.A., Costa D.B., Varella-Garcia M., Kim W.H., Lynch T.J., Fidias P., Stubbs H., Engelman J.A., Sequist L.V., Tan W., Gandhi L., Mino-Kenudson M., Wei G.C., Shreeve S.M., Ratain M.J., Settleman J., Christensen J.G., Haber D.A., Wilner K., Salgia R., Shapiro G.I., Clark J.W., Iafrate A.J. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 2010, 363:1693-1703.
56. Thunnissen E., Bubendorf L., Dietel M., Elmberger G., Kerr K., Lopez-Rios F., Moch H., Olszewski W., Pauwels P., Penault-Llorca F., Rossi G. EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Arch. 2012, 461:245-257.
57. Wong D.W., Leung E.L., So K.K., Tam I.Y., Sihoe A.D., Cheng L.C., Ho K.K., Au J.S., Chung L.P., Pik Wong M. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 2009, 115:1723-1733.
58. Cui J.J., Tran-Dube M., Shen H., Nambu M., Kung P.P., Pairish M., Jia L., Meng J., Funk L., Botrous I., McTigue M., Grodsky N., Ryan K., Padrique E., Alton G., Timofeevski S., Yamazaki S., Li Q., Zou H., Christensen J., Mroczkowski B., Bender S., Kania R.S., Edwards M.P. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J. Med. Chem. 2011, 54:6342-6363.
59. Shaw A.T., Kim D.W., Nakagawa K., Seto T., Crino L., Ahn M.J., De Pas T., Besse B., Solomon B.J., Blackhall F., Wu Y.L., Thomas M., O'Byrne K.J., Moro-Sibilot D., Camidge D.R., Mok T., Hirsh V., Riely G.J., Iyer S., Tassell V., Polli A., Wilner K.D., Janne P.A. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 2013, 368:2385-2394.
60. Song Z., Wang M., Zhang A. Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance. Acta Pharmaceutica Sin. B 2015, 5:34-37.
61. Shaw A.T., Engelman J.A. Ceritinib in ALK-rearranged non-small-cell lung cancer. N. Engl. J. Med. 2014, 370:2537-2539.
62. Ajimizu H., Kim Y.H., Mishima M. Rapid response of brain metastases to alectinib in a patient with non-small-cell lung cancer resistant to crizotinib. Med. Oncol. 2015, 32:477.
63. Doebele R.C., Pilling A.B., Aisner D.L., Kutateladze T.G., Le A.T., Weickhardt A.J., Kondo K.L., Linderman D.J., Heasley L.E., Franklin W.A., Varella-Garcia M., Camidge D.R. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin. Cancer Res. 2012, 18:1472-1482.
64. Huang D., Kim D.W., Kotsakis A., Deng S., Lira P., Ho S.N., Lee N.V., Vizcarra P., Cao J.Q., Christensen J.G., Kim T.M., Sun J.M., Ahn J.S., Ahn M.J., Park K., Mao M. Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment. Genomics 2013, 102:157-162.
65. Sasaki T., Koivunen J., Ogino A., Yanagita M., Nikiforow S., Zheng W., Lathan C., Marcoux J.P., Du J., Okuda K., Capelletti M., Shimamura T., Ercan D., Stumpfova M., Xiao Y., Weremowicz S., Butaney M., Heon S., Wilner K., Christensen J.G., Eck M.J., Wong K.K., Lindeman N., Gray N.S., Rodig S.J., Janne P.A. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res. 2011, 71:6051-6060.
66. Jiang L., Huang J., Morehouse C., Zhu W., Korolevich S., Sui D., Ge X., Lehmann K., Liu Z., Kiefer C., Czapiga M., Su X., Brohawn P., Gu Y., Higgs B.W., Yao Y. Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients. Cancer Genet. 2013, 206:330-339.
67. Kim H.R., Kim W.S., Choi Y.J., Choi C.M., Rho J.K., Lee J.C. Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation. Mol. Oncol. 2013, 7:1093-1102.
68. Bergethon K., Shaw A.T., Ou S.H., Katayama R., Lovly C.M., McDonald N.T., Massion P.P., Siwak-Tapp C., Gonzalez A., Fang R., Mark E.J., Batten J.M., Chen H., Wilner K.D., Kwak E.L., Clark J.W., Carbone D.P., Ji H., Engelman J.A., Mino-Kenudson M., Pao W., Iafrate A.J. ROS1 rearrangements define a unique molecular class of lung cancers. J. Clin. Oncol. 2012, 30:863-870.
69. Yasuda H., de Figueiredo-Pontes L.L., Kobayashi S., Costa D.B. Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. J. Thorac. Oncol. 2012, 7:1086-1090.
70. Davies K.D., Le A.T., Theodoro M.F., Skokan M.C., Aisner D.L., Berge E.M., Terracciano L.M., Cappuzzo F., Incarbone M., Roncalli M., Alloisio M., Santoro A., Camidge D.R., Varella-Garcia M., Doebele R.C. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin. Cancer Res. 2012, 18:4570-4579.
71. Shaw A.T., Ou S.H., Bang Y.J., Camidge D.R., Solomon B.J., Salgia R., Riely G.J., Varella-Garcia M., Shapiro G.I., Costa D.B., Doebele R.C., Le L.P., Zheng Z., Tan W., Stephenson P., Shreeve S.M., Tye L.M., Christensen J.G., Wilner K.D., Clark J.W., Iafrate A.J. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N. Engl. J. Med. 2014, 371:1963-1971.
72. Mazieres J., Zalcman G., Crino L., Biondani P., Barlesi F., Filleron T., Dingemans A.M., Lena H., Monnet I., Rothschild S.I., Cappuzzo F., Besse B., Thiberville L., Rouviere D., Dziadziuszko R., Smit E.F., Wolf J., Spirig C., Pecuchet N., Leenders F., Heuckmann J.M., Diebold J., Milia J.D., Thomas R.K., Gautschi O. Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort. J. Clin. Oncol. 2015.
73. Davare M.A., Saborowski A., Eide C.A., Tognon C., Smith R.L., Elferich J., Agarwal A., Tyner J.W., Shinde U.P., Lowe S.W., Druker B.J. Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins. Proc. Natl. Acad. Sci. USA 2013, 110:19519-19524.
74. Davies K.D., Mahale S., Astling D.P., Aisner D.L., Le A.T., Hinz T.K., Vaishnavi A., Bunn P.A., Heasley L.E., Tan A.C., Camidge D.R., Varella-Garcia M., Doebele R.C. Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer. PLoS One 2013, 8:e82236.
75. Song A., Kim T.M., Kim D.W., Kim S., Keam B., Lee S.H., Heo D.S. Molecular changes associated with acquired resistance to crizotinib in ROS1-rearranged non-small cell lung cancer (NSCLC). Clin. Cancer Res. 2015.
76. Cargnelutti M., Corso S., Pergolizzi M., Mevellec L., Aisner D.L., Dziadziuszko R., Varella-Garcia M., Comoglio P.M., Doebele R.C., Vialard J., Giordano S. Activation of RAS family members confers resistance to ROS1 targeting drugs. Oncotarget 2014.
77. Wang R., Hu H., Pan Y., Li Y., Ye T., Li C., Luo X., Wang L., Li H., Zhang Y., Li F., Lu Y., Lu Q., Xu J., Garfield D., Shen L., Ji H., Pao W., Sun Y., Chen H. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J. Clin. Oncol. 2012, 30:4352-4359.
78. Drilon A., Wang L., Hasanovic A., Suehara Y., Lipson D., Stephens P., Ross J., Miller V., Ginsberg M., Zakowski M.F., Kris M.G., Ladanyi M., Rizvi N. Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov 2013, 3:630-635.
79. Chao B.H., Briesewitz R., Villalona-Calero M.A. RET fusion genes in non-small-cell lung cancer. J. Clin. Oncol. 2012, 30:4439-4441.
80. Alao J.P., Michlikova S., Diner P., Grotli M., Sunnerhagen P. Selective inhibition of RET mediated cell proliferation in vitro by the kinase inhibitor SPP86. BMC Cancer 2014, 14:853.
81. Kodama T., Tsukaguchi T., Satoh Y., Yoshida M., Watanabe Y., Kondoh O., Sakamoto H. Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer. Mol. Cancer Ther. 2014, 13:2910-2918.
82. Gautschi O., Zander T., Keller F.A., Strobel K., Hirschmann A., Aebi S., Diebold J. A patient with lung adenocarcinoma and RET fusion treated with vandetanib. J. Thorac. Oncol. 2013, 8:e43-e44.
83. Mazieres J., Peters S., Lepage B., Cortot A.B., Barlesi F., Beau-Faller M., Besse B., Blons H., Mansuet-Lupo A., Urban T., Moro-Sibilot D., Dansin E., Chouaid C., Wislez M., Diebold J., Felip E., Rouquette I., Milia J.D., Gautschi O. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J. Clin. Oncol. 2013, 31:1997-2003.
84. Perera S.A., Li D., Shimamura T., Raso M.G., Ji H., Chen L., Borgman C.L., Zaghlul S., Brandstetter K.A., Kubo S., Takahashi M., Chirieac L.R., Padera R.F., Bronson R.T., Shapiro G.I., Greulich H., Meyerson M., Guertler U., Chesa P.G., Solca F., Wistuba I.I., Wong K.K. HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. Proc. Natl. Acad. Sci. USA 2009, 106:474-479.
85. Shimamura T., Ji H., Minami Y., Thomas R.K., Lowell A.M., Shah K., Greulich H., Glatt K.A., Meyerson M., Shapiro G.I., Wong K.K. Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. Cancer Res. 2006, 66:6487-6491.
86. Rafael Sierra J., Tsao M.S. c-MET as a potential therapeutic target and biomarker in cancer. Ther. Adv. Med. Oncol. 2011, 3:21-35.
87. Landi L., Minuti G., D'Incecco A., Cappuzzo F. Targeting c-MET in the battle against advanced nonsmall-cell lung cancer. Curr. Opin. Oncol. 2013, 25:130-136.
88. Calles A., Kwiatkowski N., Cammarata B.K., Ercan D., Gray N.S., Janne P.A. Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines. Mol. Oncol. 2015, 9:260-269.
89. Yamamoto N., Murakami H., Hayashi H., Fujisaka Y., Hirashima T., Takeda K., Satouchi M., Miyoshi K., Akinaga S., Takahashi T., Nakagawa K. CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer. Br. J. Cancer 2013, 109:2803-2809.
90. Sequist L.V., von Pawel J., Garmey E.G., Akerley W.L., Brugger W., Ferrari D., Chen Y., Costa D.B., Gerber D.E., Orlov S., Ramlau R., Arthur S., Gorbachevsky I., Schwartz B., Schiller J.H. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J. Clin. Oncol. 2011, 29:3307-3315.
91. Kerner G.S., Schuuring E., Sietsma J., Hiltermann T.J., Pieterman R.M., de Leede G.P., van Putten J.W., Liesker J., Renkema T.E., van Hengel P., Platteel I., Timens W., Groen H.J. Common and rare EGFR and KRAS mutations in a Dutch non-small-cell lung cancer population and their clinical outcome. PLoS One 2013, 8:e70346.
92. Katayama R., Shaw A.T., Khan T.M., Mino-Kenudson M., Solomon B.J., Halmos B., Jessop N.A., Wain J.C., Yeo A.T., Benes C., Drew L., Saeh J.C., Crosby K., Sequist L.V., Iafrate A.J., Engelman J.A. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci. Transl. Med. 2012, 4. 120ra117.